FA
ONC

FDx Advisors’s BeOne Medicines Ltd ONC Stock Holding History

FDx Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,319
Closed -$437K – 912
2022
Q1 		$437K Sell
2,319
-350
-13% -$74.4K 0.01% 539
2021
Q4 		$723K Sell
2,669
-62
-2% -$20.9K 0.02% 434
2021
Q3 		$991K Sell
2,731
-94
-3% -$30.7K 0.03% 337
2021
Q2 		$970K Sell
2,825
-48
-2% -$15.9K 0.03% 346
2021
Q1 		$1M Buy
2,873
+54
+2% +$17.9K 0.04% 296
2020
Q4 		$728K Buy
2,819
+584
+26% +$161K 0.03% 346
2020
Q3 		$640K Buy
2,235
+238
+12% +$55.9K 0.03% 322
2020
Q2 		$376K Buy
1,997
+219
+12% +$35.6K 0.02% 397
2020
Q1 		$219K Buy
1,778
+126
+8% +$19.7K 0.01% 455
2019
Q4 		$274K Sell
1,652
-62
-4% -$10.3K 0.02% 513
2019
Q3 		$210K Buy
1,714
+64
+4% +$8.5K 0.01% 592
2019
Q2 		$205K Buy
+1,650
New +$209K 0.01% 766

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

FDx Advisors's ONC Position: Q2 2022 in Review

FDx Advisors sold out of BeOne Medicines Ltd (ONC) in Q2 2022, closing a stake of 2,319 shares — an estimated $437K sold.

FDx Advisors first reported a position in ONC in Q2 2019 and held it in 12 quarters. The position peaked at $1M in Q1 2021. 235 funds tracked by Wall St. Rank hold ONC as of Q2 2022.

  • FDx Advisors reported no remaining BeOne Medicines Ltd position as of Q2 2022 after selling out during the quarter.
  • FDx Advisors sold 2,319 BeOne Medicines Ltd shares in Q2 2022, an estimated $437K.
  • FDx Advisors first reported a position in BeOne Medicines Ltd in Q2 2019 and held it in 12 quarters.
  • FDx Advisors's BeOne Medicines Ltd position peaked at $1M in Q1 2021.
  • 235 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2022.

Based on FDx Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.